Janux Therapeutics (JANX) Income Statement (2020 - 2026)
Income Statement report data from Jun 30, 2020 to Mar 31, 2026 for Janux Therapeutics (JANX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||||||
Total Revenue | 3.73M | - | 10M | - | - | - | 440K (-95.06%) | 8.90M (+612.00%) | 1.25M (-49.19%) | 2.46M (-2.38%) | 2.52M (+137.74%) | 1.06M (-48.29%) | 2.05M (-28.07%) | 2.85M (+57.46%) | 1.81M (-23.63%) | 2.37M (+49.06%) | 1.59M (-1.85%) | 1.62M (+39.66%) | 1.16M (+141.67%) | 480K (+26.32%) | 380K | - | - |
Operating Expenses | |||||||||||||||||||||||
Research And Development | 27M (-15.02%) | 32M (-8.89%) | 35M (-0.09%) | 35M (+38.31%) | 25M (+20.42%) | 21M (+11.82%) | 19M (+24.90%) | 15M (+5.90%) | 14M (+14.95%) | 12M (+2.94%) | 12M (-20.31%) | 15M (-5.99%) | 16M (+2.85%) | 15M (+12.30%) | 14M (-2.48%) | 14M (+38.41%) | 10M (-8.86%) | 11M (+32.82%) | 8.41M (+77.43%) | 4.74M (+145.60%) | 1.93M (+132.53%) | 830K (+23.88%) | 670K |
Selling General And Administrative | 11M (+2.58%) | 11M (+2.17%) | 11M (+1.63%) | 10M (+6.20%) | 9.84M (+19.71%) | 8.22M (-53.48%) | 18M (+125.96%) | 7.82M (+6.54%) | 7.34M (+15.41%) | 6.36M (-1.24%) | 6.44M (-6.40%) | 6.88M (+6.50%) | 6.46M (+13.73%) | 5.68M (-6.89%) | 6.10M (+10.11%) | 5.54M (+11.92%) | 4.95M (+25.63%) | 3.94M (+7.65%) | 3.66M (+83.00%) | 2.00M (+170.27%) | 740K (+76.19%) | 420K (-2.33%) | 430K |
Operating Expenses | 38M (-10.50%) | 42M (-6.30%) | 45M (+0.29%) | 45M (+29.28%) | 35M (+20.26%) | 29M (-20.01%) | 36M (+59.68%) | 23M (+6.12%) | 21M (+15.11%) | 19M (+1.47%) | 18M (-15.96%) | 22M (-2.33%) | 22M (+5.78%) | 21M (+6.40%) | 20M (+1.07%) | 20M (+29.74%) | 15M (+0.13%) | 15M (+25.29%) | 12M (+79.20%) | 6.73M (+153.01%) | 2.66M (+111.11%) | 1.26M (+13.51%) | 1.11M |
Depreciation And Amortization | 470K (-68.87%) | 1.51M | - | - | 520K (-66.01%) | 1.53M | - | - | 530K (-64.67%) | 1.50M | - | - | 450K (-40.79%) | 760K | - | - | 80K (-20.00%) | 100K | - | - | 10K | - | - |
Operating Income | |||||||||||||||||||||||
Operating Income | -34.21M (-19.32%) | -42.40M (+20.28%) | -35.25M (-21.88%) | -45.12M (+29.28%) | -34.90M (+20.26%) | -29.02M (-19.03%) | -35.84M (+159.33%) | -13.82M (-31.45%) | -20.16M (+24.91%) | -16.14M (+2.09%) | -15.81M (-23.81%) | -20.75M (+2.32%) | -20.28M (+11.00%) | -18.27M (+1.39%) | -18.02M (+4.40%) | -17.26M (+27.47%) | -13.54M (+0.37%) | -13.49M (+23.76%) | -10.90M (+74.40%) | -6.25M (+174.12%) | -2.28M (+80.95%) | -1.26M (+13.51%) | -1.11M |
Ebit | -34.21M (-19.32%) | -42.40M (+20.28%) | -35.25M (-21.88%) | -45.12M (+29.28%) | -34.90M (+20.26%) | -29.02M (-19.03%) | -35.84M (+159.33%) | -13.82M (-31.45%) | -20.16M (+24.91%) | -16.14M (+2.09%) | -15.81M (-23.81%) | -20.75M (+2.32%) | -20.28M (+11.00%) | -18.27M (+1.39%) | -18.02M (+4.40%) | -17.26M (+27.47%) | -13.54M (+0.37%) | -13.49M (+23.76%) | -10.90M (+74.40%) | -6.25M (+174.12%) | -2.28M (+80.95%) | -1.26M (+13.51%) | -1.11M |
EBITDA | -33.74M (-46.52%) | -63.09M (+159.52%) | -24.31M (-28.20%) | -33.86M (-1.51%) | -34.38M (-20.31%) | -43.14M (+53.74%) | -28.06M (+370.81%) | -5.96M (-69.64%) | -19.63M (-11.26%) | -22.12M (+91.18%) | -11.57M (-33.92%) | -17.51M (-11.70%) | -19.83M (+3.28%) | -19.20M (+14.97%) | -16.70M (-1.12%) | -16.89M (+25.48%) | -13.46M (-0.81%) | -13.57M (+26.00%) | -10.77M (+73.43%) | -6.21M (+173.57%) | -2.27M (+80.16%) | -1.26M (-48.78%) | -2.46M |
Other Income / Expenses | |||||||||||||||||||||||
Other Non Operating Income | 9.85M (-77.63%) | 44M (+302.56%) | 11M (-2.84%) | 11M (-1.14%) | 11M (-61.84%) | 30M (+283.68%) | 7.78M (-1.02%) | 7.86M (+45.56%) | 5.40M (-63.24%) | 15M (+245.65%) | 4.25M (+31.17%) | 3.24M (+14.89%) | 2.82M (-30.02%) | 4.03M (+203.01%) | 1.33M (+259.46%) | 370K (+184.62%) | 130K (-50.00%) | 260K (+85.71%) | 140K (+180.00%) | 50K | - | - | -1.35M |
Net Income | |||||||||||||||||||||||
Net Income From Continuing Operations | -24.36M (-23.76%) | -31.95M (+31.43%) | -24.31M (-28.20%) | -33.86M (+44.02%) | -23.51M (+16.27%) | -20.22M (-27.94%) | -28.06M (+370.81%) | -5.96M (-59.62%) | -14.76M (+25.51%) | -11.76M (+1.64%) | -11.57M (-33.92%) | -17.51M (+0.29%) | -17.46M (+8.65%) | -16.07M (-3.77%) | -16.70M (-1.12%) | -16.89M (+25.95%) | -13.41M (-0.07%) | -13.42M (+24.61%) | -10.77M (+73.43%) | -6.21M (+172.37%) | -2.28M (+80.95%) | -1.26M (-48.78%) | -2.46M |
Net Income | -24.36M (-23.76%) | -31.95M (+31.43%) | -24.31M (-28.20%) | -33.86M (+44.02%) | -23.51M (+16.27%) | -20.22M (-27.94%) | -28.06M (+370.81%) | -5.96M (-59.62%) | -14.76M (+25.51%) | -11.76M (+1.64%) | -11.57M (-33.92%) | -17.51M (+0.29%) | -17.46M (+8.65%) | -16.07M (-3.77%) | -16.70M (-1.12%) | -16.89M (+25.95%) | -13.41M (-0.07%) | -13.42M (+24.61%) | -10.77M (+73.43%) | -6.21M (+172.37%) | -2.28M (+80.95%) | -1.26M (-48.78%) | -2.46M |
Comprehensive Income Net Of Tax | -28.10M (-74.79%) | -111.47M (+374.34%) | -23.50M (-30.62%) | -33.87M (+54.59%) | -21.91M (-67.54%) | -67.50M (+262.71%) | -18.61M (+163.97%) | -7.05M (-55.80%) | -15.95M (-71.56%) | -56.09M (+380.22%) | -11.68M (-34.49%) | -17.83M (+7.02%) | -16.66M (-74.10%) | -64.32M (+276.80%) | -17.07M (-0.93%) | -17.23M (+15.02%) | -14.98M (-54.52%) | -32.94M (+206.13%) | -10.76M (+73.83%) | -6.19M (+171.49%) | -2.28M (+80.95%) | -1.26M (-48.78%) | -2.46M |